股票近期走势 以上内容基于公开资料整理，不构成投资建议。 经济观察网远大控股（000626）公告称，公司及控股子公司无逾期担保、无涉及诉讼的担保情形。本次 担保后，公司对外担保额度总金额为106.54亿元，占2024年度经审计净资产的453.42%，均为金融机构 授信类担保，实际使用授信余额为33.05亿元(截至2025年第三季度报告期末)。该公告旨在澄清公司担保 风险可控，可能对投资者情绪产生稳定作用。 近期远大控股股价呈现震荡下行趋势。截至2026年2月12日收盘，股价报7.47元，单日下跌3.11%，成交 额7356万元；近5日累计跌幅达2.73%，表现弱于大盘及物流板块。资金流向显示当日主力净流出93.70 万元，散户资金小幅净流入，反映市场分歧较大。技术面上，股价触及20日布林线下轨(7.46元)附近支 撑位，MACD指标维持负值，短期需关注能否企稳。 ...

证券代码：000626 证券简称：远大控股 公告编号：2026-005 远大产业控股股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别风险提示： 公司及控股子公司对外担保总额超过公司最近一期经审计净资产 100%；对资产负债率 超过 70%的单位担保金额超过公司最近一期经审计净资产 50%，敬请投资者关注风险。 一、担保情况概述 远大产业控股股份有限公司（以下简称：公司）与银行签署合同，为公司的 子公司申请授信提供担保，担保金额不超过 6.66 亿元。本次担保的具体金额如 下： 1、公司为全资子公司远大物产集团有限公司（以下简称：远大物产）、宁 波远大国际贸易有限公司（以下简称：宁波远大）向中国农业银行股份有限公司 宁波海曙支行（以下简称：农业银行）申请授信提供担保，担保金额分别不超过 1.8 亿元、6,000 万元。 2、公司为控股子公司远大能源化工有限公司（以下简称：远大能化）、浙 江新景进出口有限公司（以下简称：浙江新景）向农业银行申请授信提供担保， 担保金额分别不超过 2.4 亿元、3,600 万元。 3 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示： 公司及控股子公司对外担保总额超过公司最近一期经审计净资产100%；对资产负债率超过70%的单位 担保金额超过公司最近一期经审计净资产50%，敬请投资者关注风险。 一、担保情况概述 远大产业控股股份有限公司（以下简称：公司）与交通银行股份有限公司渭南分行（以下简称：交通银 行）签署合同，为公司全资子公司远大作物科学（陕西）有限公司[以下简称：远大作物科学（陕西）] 申请授信提供担保，担保金额不超过600万元。 公司于2025年12月12日、12月29日分别召开第十一届董事会2025年度第十次会议、2025年度第二次临时 股东会审议通过了《关于2026年度为子公司提供担保预计额度的议案》，详见公司2025年12月13日、12 月30日披露于《中国证券报》、《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）的《董事会决 议公告》、《关于2026年度为子公司提供担保预计额度的公告》和《2025年度第二次临时股东会决议公 告》。 单 ...

证券代码：000626 证券简称：远大控股 公告编号：2026-004 远大产业控股股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别风险提示： 公司及控股子公司对外担保总额超过公司最近一期经审计净资产 100%；对资产负债率 超过 70%的单位担保金额超过公司最近一期经审计净资产 50%，敬请投资者关注风险。 一、担保情况概述 远大产业控股股份有限公司（以下简称：公司）与交通银行股份有限公司渭 南分行（以下简称：交通银行）签署合同，为公司全资子公司远大作物科学（陕 西）有限公司[以下简称：远大作物科学（陕西）]申请授信提供担保，担保金额 不超过 600 万元。 公司于 2025 年 12 月 12 日、12 月 29 日分别召开第十一届董事会 2025 年度 第十次会议、2025 年度第二次临时股东会审议通过了《关于 2026 年度为子公司 提供担保预计额度的议案》，详见公司 2025 年 12 月 13 日、12 月 30 日披露于 《中国证券报》、《证券时报》和巨潮资讯网（http://www.cninfo ...

Core Viewpoint - The company, Far East Holdings (000626.SZ), anticipates a net loss of 60 million to 120 million yuan for the fiscal year 2025, compared to a loss of 301.76 million yuan in the same period last year [1] Financial Performance - The expected net loss for 2025 is between 60 million and 120 million yuan, while the adjusted net loss (excluding non-recurring items) is projected to be between 120 million and 240 million yuan, compared to 554.81 million yuan in the previous year [1] - The primary reason for the losses is the impairment testing of goodwill related to investment acquisitions, influenced by macroeconomic slowdown and underperformance of acquired assets [1] Goodwill Impairment - The company plans to recognize a goodwill impairment provision of 75 million to 150 million yuan based on cautious judgment regarding the existence of impairment signs [1] Business Model Impact - The company employs a business model that combines spot and futures trading in the commodity trading sector, leading to significant differences in net profit before and after excluding non-recurring items, although this does not affect the company's actual operational capabilities [1]

Financial Performance Expectations - The company expects a net loss attributable to shareholders between 60 million and 120 million yuan for the fiscal year 2025, compared to a loss of 301.76 million yuan in the same period last year[4]. - The expected loss excluding non-recurring gains and losses is projected to be between 120 million and 240 million yuan, compared to a loss of 554.81 million yuan in the previous year[4]. - The basic earnings per share are anticipated to be a loss of 0.12 to 0.24 yuan per share, compared to a loss of 0.59 yuan per share in the prior year[4]. Reasons for Expected Loss - The primary reason for the expected loss is the impairment testing of goodwill related to investment acquisitions, with an estimated impairment provision of 75 million to 150 million yuan due to macroeconomic slowdown and underperformance of acquired assets[7]. Business Model and Financial Reporting - The company operates a business model in commodity trading that combines spot and futures, leading to significant differences in net profit before and after excluding non-recurring gains and losses[8]. - The detailed financial data for the fiscal year 2025 will be disclosed in the annual report, with the selected media for information disclosure being "China Securities Journal," "Securities Times," and the Giant Tide Information Network[9].

远大控股公告称，2025年公司预计亏损，归属于上市公司股东的净利润为-6000万元至-12000万元，上 年同期亏损30175.89万元；扣非后净利润为-12000万元至-24000万元，上年同期亏损55480.59万元；基 本每股收益亏损0.12-0.24元/股。业绩亏损主因是公司预计计提商誉减值准备7500-15000万元，且期现结 合业务模式使扣非前后净利润差异较大。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别风险提示： 公司及控股子公司对外担保总额超过公司最近一期经审计净资产 100%；对资产负债率 超过 70%的单位担保金额超过公司最近一期经审计净资产 50%，敬请投资者关注风险。 证券代码：000626 证券简称：远大控股 公告编号：2026-002 远大产业控股股份有限公司 关于为子公司提供担保及子公司互相提供担保的进展公告 一、担保情况概述 远大产业控股股份有限公司（以下简称：公司）及公司全资子公司远大物产 集团有限公司（以下简称：远大物产）与银行签署合同，为公司的子公司申请授 信提供担保，担保金额不超过 1.2 亿元。本次担保的具体金额如下： 1、远大物产为控股子公司浙江新景进出口有限公司（以下简称：浙江新景） 向中国建设银行股份有限公司宁波分行（以下简称：建设银行）申请授信提供担 保，担保金额不超过 2,000 万元。 2、公司为远大物产、控股子公司远大石油化学有限公司（以下简称：远大 油化）向江苏银行股份有限公司宁波分行（以下简称：江苏银行）申请授信提供 担保，担保金额分别不超过 5,000 万元。 ...

Group 1 - The board of directors of Yuanda Holdings approved the establishment of a traditional Chinese medicine (TCM) seed industry company, with a unanimous vote of 14 in favor [1] - The company will invest 81.25 million yuan through its wholly-owned subsidiary, Yuanda Biological Agriculture Co., Ltd., in collaboration with Gansu Hebo Long Medicine Technology Co., Ltd. and Professor Shao Baoping's team [1] - The new company will focus on three core areas: the creation of quality resources and biobreeding technology for TCM materials like Codonopsis pilosula and Astragalus membranaceus, the development of soilless seedling breeding technology, and the deep development and commercialization of TCM health products [1] Group 2 - Codonopsis pilosula is a key TCM material known for its ability to enhance energy and nourish the lungs, with a market sales forecast of approximately 8.5 billion yuan in 2024, and a total market size of 14.86 billion yuan when including the entire industry chain [2] - The market for Codonopsis pilosula is expected to grow at an annual rate of 9% to 12%, potentially exceeding 13.5 billion to 28 billion yuan by 2030 [2] - Astragalus membranaceus is recognized for its multiple health benefits, with a projected market sales of around 18.5 billion yuan in 2024, and a total market size of 30 billion yuan by 2030, growing at an annual rate of 8% to 10% [3] Group 3 - Yuanda Biological Agriculture Co., Ltd. has established a comprehensive strategic development plan since 2021, focusing on core agricultural inputs such as biopesticides and biofertilizers [3] - The company aims to provide integrated support for the production of high-end functional health foods, covering the entire process from quality resource creation to standard control in processing [3] - The collaboration represents the first industrial chain layout in the TCM field for Yuanda Holdings, leveraging biotechnological innovation to upgrade the traditional TCM industry [4]

Core Viewpoint - Yuan Da Holdings (000626.SZ) has signed a cooperation agreement to establish a traditional Chinese medicine seed industry company, focusing on the creation of seed quality and biological breeding, as well as the commercialization of health products [1] Group 1: Company Investment and Structure - Yuan Da Bio-Agriculture Co., Ltd., a wholly-owned subsidiary of Yuan Da Holdings, will invest 81.25 million yuan to acquire a 65% stake in the new company [1] - Gansu Hebo Long Pharmaceutical Technology Co., Ltd. will contribute intangible and tangible assets related to the entire industry chain of traditional Chinese medicine breeding, valued at 43.75 million yuan, for a 35% stake [1] Group 2: Business Focus and Development - The new company will engage in the research and industrialization of modern agricultural facilities, soilless seedling breeding technology, and the deep development and commercialization of traditional Chinese health products [1]